The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma
Open accessAbstract
Purpose: In studies of diffuse large B-cell lymphoma, positron emission tomography with [ 18 F]fluorodeoxyglucose (FDG-PET) performed after two to four cycles of chemotherapy has demonstrated prognostic significance. However, some patients treated with immunochemotherapy experience a favorable long-term outcome despite a positive interim FDG-PET scan. To clarify the significance of interim FDG-PET scans, we prospectively studied interim FDG-positive disease within a risk-adapted sequential immunochemotherapy program. Patients and Methods: From March 2002 to November 2006, 98 patients at Memorial Sloan-Kettering Cancer Center received induction therapy with four cycles of accelerated R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by an interim FDG-PET scan. If the FDG-PET scan was negative, patients received three cycles of ICE (ifosfamide, carboplatin, and etoposide) consolidation therapy. If residual FDG-positive disease was seen, patients underwent biopsy; if the biopsy was negative, they also received three cycles of ICE. Patients with a positive biopsy received ICE followed by autologous stem-cell transplantation. Results: At a median follow-up of 44 months, overall and progression-free survival were 90% and 79%, respectively. Ninety-seven patients underwent interim FDG-PET scans; 59 had a negative scan, 51 of whom are progression free. Thirty-eight patients with FDG-PET–positive disease underwent repeat biopsy; 33 were negative, and 26 remain progression free after ICE consolidation therapy. Progression-free survival of interim FDG-PET–positive/biopsy-negative patients was identical to that in patients with a negative interim FDG-PET scan (P = .27). Conclusion: Interim or post-treatment FDG-PET evaluation did not predict outcome with this dose-dense, sequential immunochemotherapy program. Outside of a clinical trial, we recommend biopsy confirmation of an abnormal interim FDG-PET scan before changing therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coiffier, B., Lepage, E., Brière, J., Herbrecht, R., Tilly, H., Bouabdallah, R., Morel, P., Van Den Neste, E., Salles, G., Gaulard, P., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011795 · Cited by 5,574
A Predictive Model for Aggressive Non-Hodgkin's Lymphoma
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291402 · Cited by 4,949
Revised Response Criteria for Malignant Lymphoma
Cheson, B. D., Pfistner, B., Juweid, M. E., Gascoyne, R. D., Specht, L., Horning, S. J., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,426
Fisher, R. I., Gaynor, E. R., Dahlberg, S., Oken, M. M., Grogan, T. M., Mize, E. M., Glick, J. H., Coltman, C. A., & Miller, T. P. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304083281404 · Cited by 2,149
Perkins, N. J., & Schisterman, E. F. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj063 · Cited by 1,759
Young, H., Baum, R., Cremerius, U., Herholz, K., Hoekstra, O., Lammertsma, A. A., Pruim, J., & Price, P. (1999) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00229-4 · Cited by 1,720
Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P., Klasa, R., Savage, K. J., Shenkier, T., Sutherland, J., et al. (2007) · Blood · doi:10.1182/blood-2006-08-038257 · Cited by 1,473
Juweid, M. E., Stroobants, S., Hoekstra, O. S., Mottaghy, F. M., Dietlein, M., Guermazi, A., Wiseman, G. A., Kostakoglu, L., Scheidhauer, K., Buck, A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2305 · Cited by 1,335
Pfreundschuh, M., Schubert, J., Ziepert, M., Schmits, R., Mohren, M., Lengfelder, E., Reiser, M., Nickenig, C., Clemens, M., Peter, N., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70002-0 · Cited by 1,130
Sehn, L. H., Donaldson, J., Chhanabhai, M., Fitzgerald, C., Gill, K., Klasa, R., MacPherson, N., O'Reilly, S., Spinelli, J. J., Sutherland, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.137 · Cited by 987
Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6525 · Cited by 846
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
Hutchings, M., Loft, A., Hansen, M., Pedersen, L. M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.-M., et al. (2006) · Blood · doi:10.1182/blood-2005-06-2252 · Cited by 726
From the bench to the bedside: ways to improve rituximab efficacy
Cartron, G., Watier, H., Golay, J., & Solal-Celigny, P. (2004) · Blood · doi:10.1182/blood-2004-03-1110 · Cited by 523
Haioun, C., Itti, E., Rahmouni, A., Brice, P., Rain, J.-D., Belhadj, K., Gaulard, P., Garderet, L., Lepage, E., Reyes, F., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0272 · Cited by 494
Spaepen, K., Stroobants, S., Dupont, P., Van Steenweghen, S., Thomas, J., Vandenberghe, P., Vanuytsel, L., Bormans, G., Balzarini, J., De Wolf-Peeters, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.414 · Cited by 465
Spaepen, K., Stroobants, S., Dupont, P., Vandenberghe, P., Thomas, J., de Groot, T., Balzarini, J., De Wolf-Peeters, C., Mortelmans, L., & Verhoef, G. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf256 · Cited by 410
Kewalramani, T., Zelenetz, A. D., Nimer, S. D., Portlock, C., Straus, D., Noy, A., O'Connor, O., Filippa, D. A., Teruya-Feldstein, J., Gencarelli, A., et al. (2004) · Blood · doi:10.1182/blood-2003-11-3911 · Cited by 406
Self-citationJuweid, M. E., Wiseman, G. A., Vose, J. M., Ritchie, J. M., Menda, Y., Wooldridge, J. E., Mottaghy, F. M., Rohren, E. M., Blumstein, N. M., Stolpen, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.891 · Cited by 387
Mazumdar, M., & Glassman, J. R. (2000) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(20000115)19:1<113::aid-sim245>3.0.co;2-o · Cited by 367
Wilson, W. H., Dunleavy, K. M., Pittaluga, S., Hegde, U. P., Grant, N., Steinberg, S. M., Raffeld, M. A., Gutierrez, M. E., Chabner, B. A., Staudt, L. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1391 · Cited by 326
Moskowitz, C. H., Bertino, J. R., Glassman, J. R., Hedrick, E. E., Hunte, S., Coady-Lyons, N., Agus, D. B., Goy, A., Jurcic, J., Noy, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3776 · Cited by 302
Self-citationJerusalem, G., Beguin, Y. P., Fassotte, M., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (2000) · PubMed · Cited by 203
Bunder, M. W. (1976) · Journal of Symbolic Logic · doi:10.1017/s0022481200051537 · Cited by 160
Han, H. S., Escalón, M. P., Hsiao, B., Serafini, A. N., & Lossos, I. S. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn629 · Cited by 154
Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz, C. H., Glassman, J. R., Wuest, D. L., Maslak, P. G., REICH, L. M., Gucciardo, A., Lyons, N. C., Zelenetz, A. D., & Nimer, S. D. (1998) · PubMed · Cited by 121
Self-citationReceiver Operating Characteristic Studies and Measurement Errors
Coffin, M., & Sukhatme, S. (1997) · Biometrics · doi:10.2307/2533545 · Cited by 113
Preclinical and phase I and II trials of rituximab.
Maloney, D. G. (1999) · PubMed · Cited by 105
Fruchart, C., Reman, O., Stang, N. L., Musafiri, D., Chèze, S., Macro, M., Switsers, O., Aide, N., Liegard, M., Levaltier, X., et al. (2006) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190600942959 · Cited by 32
Zhao, S., Kuge, Y., Kohanawa, M., Takahashi, T., Kawashima, H., Temma, T., Takei, T., Zhao, Y., Seki, K., & Tamaki, N. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0529-8 · Cited by 25
(1950) · doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-3
Cited by
Synthetic lethal metabolic targeting of cellular senescence in cancer therapy
Dörr, J. R., Yu, Y., Milanovic, M., Beuster, G., Zasada, C., Däbritz, J. H. M., Lisec, J., Lenze, D., Gerhardt, A., Schleicher, K., et al. (2013) · Nature · doi:10.1038/nature12437 · Cited by 541
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Friedberg, J. W. (2011) · Hematology · doi:10.1182/asheducation-2011.1.498 · Cited by 497
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F. M., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.5246 · Cited by 497
Scherer, F., Kurtz, D. M., Newman, A. M., Stehr, H., Craig, A. F. M., Esfahani, M. S., Lovejoy, A. F., Chabon, J. J., Klass, D. M., Liu, C. L., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aai8545 · Cited by 484
Roschewski, M., Dunleavy, K., Pittaluga, S., Moorhead, M., Pepin, F., Kong, K., Shovlin, M., Jaffe, E. S., Staudt, L. M., Lai, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70106-3 · Cited by 463
Metadata
- Authors
- Moskowitz, C. H., Schöder, H., Teruya-Feldstein, J., Sima, C., Iasonos, A., Portlock, C. S., Straus, D., Noy, A., Palomba, M. L., O'Connor, O. A., Horwitz, S., Weaver, S. A., Meikle, J. L., Filippa, D. A., Caravelli, J. F., Hamlin, P. A., & Zelenetz, A. D.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-04-10
- Volume
- 28
- Issue
- 11
- Pages
- 1896-1903
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2130929003
- Cited by
- 326
- References
- 33
- FWCI
- 18.46
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.